从肺动脉高血压患者中分离出循环内皮细胞的特征性疾病缺陷
Kulwant S Aulak1, Lori Mavarakis1, Liping Tian1
1Department of Immunology and Immunity, Cleveland Clinic, Lerner Research Institute, Cleveland, Ohio, United States of America.
PloS one
|October 28, 2024
概括
研究人员开发了一种新的方法来培养来自肺动脉高血压 (PAH) 患者的循环内皮细胞 (CEC). 这些CEC揭示了关键的疾病途径,有助于制定PAH个性化治疗策略.
科学领域:
- 心血管医学 心血管医学
- 细胞生物学 细胞生物学
- 肺高血压研究 肺高血压研究
背景情况:
- 肺动脉高血压 (PAH) 是一种导致右心力衰竭的严重疾病.
- 目前的治疗方法可以改善存活率,但不能提供治愈.
- 现有的研究方法,如动物模型和末期患者样本,在了解PAH病原性方面存在局限性.
研究的目的:
- 建立一种新的方法来隔离和培养来自PAH患者的循环内皮细胞.
- 调查这些CEC作为研究PAH机制模型的实用性.
- 探索CEC在指导PAH个性化治疗决策方面的潜力.
主要方法:
- 在右心导管治疗期间,从PAH患者中分离和培养循环内皮细胞 (CEC).
- 对培养的CEC进行转录组分析,以评估基因表达特征.
- 将CEC基因表达与已知的PAH通路进行比较.
主要成果:
- 成功建立了从PAH患者中培养CEC的方法.
- PAH CECs表现出与该疾病相关的特征基因表达模式.
- 在CEC中观察到显著的基因表达变化,与氧化,内素,前环素和BMP/活性蛋白通路有关.
结论:
- 培养的CEC为PAH的机制性评估提供了一个可行的实体模型.
- 这种细胞模型反映了PAH病变发生的关键分子通路.
- 对于推进个性化医疗和治疗策略,PAH CECs具有前景.
相关概念视频
01:30Peripheral Artery Disease I: Introduction
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs but also impacts other areas, such as the arms, thereby impairing overall circulation and organ function.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty deposits inside the arterial...
01:30Pulmonary Hypertension: Classification and Pathogenesis
151
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
151
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
136
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
136